@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_head { this: np:hasAssertion dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_assertion; np:hasProvenance dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_provenance; np:hasPublicationInfo dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_publicationInfo; a np:Nanopublication . dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_assertion a np:Assertion . dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_provenance a np:Provenance . dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_publicationInfo a np:PublicationInfo . } dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_assertion { miriam-gene:2324 a ncit:C16612 . lld:C0027627 a ncit:C7057 . dgn-gda:DGNffc302bc7e8da6f19b32201ca4ddbd26 sio:SIO_000628 miriam-gene:2324, lld:C0027627; a sio:SIO_001121 . } dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_provenance { dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_assertion dcterms:description "[The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-α/β, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-κB ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:23666471; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1077055.RA0IaydA4YYuyUD_2otP1HHOatOmlrLEcgSA6j0fPVYdo130_publicationInfo { this: dcterms:created "2016-05-13T12:49:54+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }